FRA: 6BU0

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond
CompanyDrug

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

AbbVie Inc. (NYSE: ABBV) announced the official launch in China of Epkinly (epcoritamab), a CD3×CD20 bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma…

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Sunvozertinib's Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China
CompanyDrug

Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China